{
    "paper_id": "PMC6795539",
    "metadata": {
        "title": "A single T cell epitope drives the neutralizing anti-drug antibody\nresponse to natalizumab in multiple sclerosis patients",
        "authors": [
            {
                "first": "Antonino",
                "middle": [],
                "last": "Cassotta",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Vincent",
                "middle": [],
                "last": "Mikol",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Thomas",
                "middle": [],
                "last": "Bertrand",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "St\u00e9phanie",
                "middle": [],
                "last": "Pouzieux",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Josiane",
                "middle": [],
                "last": "Le Parc",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Paul",
                "middle": [],
                "last": "Ferrari",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jacques",
                "middle": [],
                "last": "Dumas",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Michael",
                "middle": [],
                "last": "Auer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Florian",
                "middle": [],
                "last": "Deisenhammer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Matteo",
                "middle": [],
                "last": "Gastaldi",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Diego",
                "middle": [],
                "last": "Franciotta",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Chiara",
                "middle": [],
                "last": "Silacci-Fregni",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Blanca",
                "middle": [],
                "last": "Fernandez Rodriguez",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Isabella",
                "middle": [],
                "last": "Giacchetto-Sasselli",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Mathilde",
                "middle": [],
                "last": "Foglierini",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "David",
                "middle": [],
                "last": "Jarrossay",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Roger",
                "middle": [],
                "last": "Geiger",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Federica",
                "middle": [],
                "last": "Sallusto",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Antonio",
                "middle": [],
                "last": "Lanzavecchia",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Luca",
                "middle": [],
                "last": "Piccoli",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Blood samples were collected from two MS patients (A and B) who had a\nhypersensitivity reaction following infusion of NZM and developed high titers of\nADAs. Patient A was treated with NZM at the University Hospital for Neurology in\nInnsbruck, Austria, in 2014, while patient B was treated at the Mondino\nFoundation in Pavia, Italy, in 2018. Both patients provided written informed\nconsent for this study. The study was approved by the Ethical committees of\nInnsbruck (UN2013-0040_LEK) and Pavia (P-20170027756). Blood samples were\nprocessed to obtain serum and peripheral blood mononuclear cells (PBMCs). For\nserum preparation, whole blood was collected in Vacutainer tubes (BD\nBiosciences) containing clot activators and kept at room temperature until a\nclot was formed. The tube was centrifuged at 2,000g for 10 min at 22\u00b0C,\nand the serum fraction was stored at \u221280\u00b0C. PBMCs were isolated\nfrom whole blood through Ficoll density gradient centrifugation and were\nresuspended in freezing medium for long-term storage in liquid nitrogen.",
            "cite_spans": [],
            "section": "Patients and sample collection ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "A variant of NZM in which the human Fc was replaced with the murine\ncounterpart (NZM-mFc) was produced by molecular cloning and used in ELISA and\nFACS assays to avoid reactivity with secondary anti-human Fc\u03b3-specific\nantibodies. Briefly, synthetic genes expressing the NZM heavy chain and light\nchain variable regions (KEGG DRUG Database entry: D06886) were produced by\nGenscript and sublconed into vectors for expression of chimeric human CH1-murine\nIgG2a heavy chain (mFc) and human Ig\u03ba, respectively. The chains were\nexpressed following transient transfection of these vectors into Expi293F cells\n(ThermoFisher Scientific) using polyethylenimine. Cell lines were routinely\ntested for mycoplasma contamination. NZM CDR swap variants were designed by\naligning the sequences of NZM with those of the human antibodies\n(21/28\u2019CL and REI) used for humanization (GenBank accession numbers\nAAA52825 and 751419A), synthetized by Genscript and subcloned into the mFc\nvector. NZM deimmunized variants were synthetized by Genscript and subcloned\ninto vectors for expression of full human IgG4. The antibodies were purified by\nprotein A or protein G chromatography (GE Healthcare) and concentrated by Amicon\nUltra filter units (100K, Millipore). For SPR, mass-spectrometry and T cell\nexperiments, NZM IgG was purified from TYSABRI\u00ae drug solution for\ninfusion (Biogen). Total IgGs were quantified by Pierce BCA protein assay\n(ThermoFischer).",
            "cite_spans": [],
            "section": "Production of NZM Fc-variants and CDR swap variants ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "Monocytes were isolated from PBMCs by positive selection using CD14\nmagnetic microbeads (Miltenyi Biotech). CD14-depleted fractions were stained on\nice for 15\u201320 min with the following fluorochrome-labeled mouse\nmonoclonal antibodies: CD8-PE\u2013Cy5 (clone B9.11; cat. no. A07758),\nCD14-PE\u2013Cy5 (clone RMO52; cat. no. A07765), CD16-PE\u2013Cy5 (clone\n3G8; cat. no. A07767), CD45RA-FITC (clone ALB11; cat. no. A07786) from Beckman\nCoulter, CD19-PE\u2013Cy7 (clone SJ25C1; cat. no. 341113), CD25\u2013PE\n(clone M-A251; cat. no. 555432) from BD Biosciences, CD4\u2013PE\u2013Texas\nRed (clone S3.5; cat. no. MHCD0417) from ThermoFisher Scientific,\nCCR7\u2013BV421 (clone G043H7; cat. no. 353208) from BioLegend, Alexa Fluor\n647-conjugated goat anti-human IgG (cat. no. 109-606-170) from Jackson\nImmunoResearch. IgG+ memory B cells were sorted from CD19+\nB cells to over 98% purity on a FACSAria III (BD). Memory CD4+ T\ncells were sorted to over 98% purity after exclusion of na\u00efve\nCD4+ T cells (CD45RA+CCR7+) and\nCD8+, CD14+, CD16+, CD19+,\nCD25bright cells.",
            "cite_spans": [],
            "section": "B cell and T cell sorting ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "B cells were cultured in RPMI 1640 medium supplemented with 2 mM\nglutamine, 1% (v/v) nonessential amino acids, 1% (v/v) sodium pyruvate,\npenicillin (50 U/ml), streptomycin (50 \u03bcg/ml) (all from Invitrogen) and\n10% fetal bovine serum (HyClone, characterized, GE Healthcare Life Science).\nSorted IgG+ memory B cells were immortalized with Epstein\u2013Barr\nvirus (EBV) and plated in single-cell cultures in the presence of CpG-DNA (2.5\n\u03bcg/ml) and irradiated PBMC-feeder cells, as previously\ndescribed12. Two weeks\npost immortalization, the culture supernatants were tested by ELISA for binding\nto NZM-mFc as well as to a control antibody of an irrelevant specificity. B cell\ncultures that tested positive only for NZM-mFc were isolated and expanded.",
            "cite_spans": [
                {
                    "start": 492,
                    "end": 494,
                    "mention": "12",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "B cell immortalization and isolation of monoclonal antibodies ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "cDNA was synthesized from selected B cell cultures, and both the VH and\nVL genes were sequenced as previously described22. The genes that encoded the VH and VL and the\nnumber of somatic mutations were determined by analyzing the homology between\nthe genes encoding the VH and VL sequences of the monoclonal antibodies and the\nknown genes encoding human V, D and J regions that are present in the\ninternational immunogenetics information system (IMGT) database (version\n3.4.17)23.\nAntibody-coding sequences were amplified and sequenced with primers specific for\nthe V and J regions of the given antibody. Sequences of the unmutated common\nancestor (UCA) of the VH- and VL-coding genes were constructed using\nIMGT/V-QUEST23 and\nsynthetized by Genscript. To calculate the frequency of mutations, the entire\nsequence of each heavy chain variable region was compared to the germline\nsequence to identify replacement (R) and silent (S) mutations. The selection\nstrength was estimated using BASELINe framework which compares the observed\nfrequencies of replacement and silent mutations with the expected ones24. All calculations were done\nusing the \u201ccalcBaseline\u201d and \u201cgroupBaseline\u201d\nfunctions from SHazaM (version 0.1.11)25. Sequences encoding antibody heavy and light chains\nwere cloned into vectors for expression of human IgG1, Ig\u03ba and\nIg\u03b3, and the chains were expressed following transient transfection of\nthese vectors into Expi293F cells, as described above. Selected antibodies were\nalso expressed as antigen-binding fragments for X-ray crystallography\nanalysis.",
            "cite_spans": [
                {
                    "start": 119,
                    "end": 121,
                    "mention": "22",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 476,
                    "end": 478,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 719,
                    "end": 721,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 1101,
                    "end": 1103,
                    "mention": "24",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 1215,
                    "end": 1217,
                    "mention": "25",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "Sequence analysis of antibody cDNAs and production of recombinant\nantibodies ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "Total IgGs were quantified using 96-well MaxiSorp plates (Nunc) coated\nwith 10 \u03bcg/ml goat anti\u2013human IgG (SouthernBiotech, cat. no.\n2040-01). Plates were then blocked with PBS with 1% BSA and incubated with\ntitrated monoclonal antibodies, using Certified Reference Material 470\n(ERMs-DA470, Sigma-Aldrich) as a standard. Plates were then washed and incubated\nwith 1/500 alkaline phosphatase (AP)-conjugated goat anti\u2013human IgG\n(Southern Biotech, cat. no. 2040-04). Substrate (para-nitrophenyl phosphate\n(p-NPP), Sigma) was added and plates were read at wavelength of 405 nm to\ndetermine optical density (OD) values. To test specific antibody binding, ELISA\nplates were coated with 1 \u03bcg/ml of NZM-mFc or a control antibody to test\nfor nonspecific binding. Plates were blocked with PBS with 1% BSA and incubated\nwith titrated sera or monoclonal antibodies, followed by 1/2,500 AP-conjugated\ngoat anti-human IgG, Fc\u03b3 fragment specific antibody (Jackson\nImmunoResearch, cat. no. 109-056-098), goat anti-human serum IgA, \u03b1 chain\nspecific (Jackson ImmunoResearch, cat. no. 109-055-011), or goat anti-human IgM,\nFc5\u03bc fragment specific (Jackson ImmunoResearch, cat. no. 109-055-129). In\nsome dissociation assays, the samples were supplemented with 25% (vol/vol) of an\nalkaline dissociation buffer (2.5% Triton X-100, 2M ethanolamine, 0.15M NaCl, pH\n11.6) one minute before the end of incubation. To test antibody binding to NZM\nCDR swap variants, ELISA plates were coated with 2 \u03bcg/ml goat\nanti\u2013mouse IgG, human adsorbed (Southern Biotech, cat. no. 1030-01) and\nblocked with PBS with 1% BSA. After washing, the plates were incubated with 2\n\u03bcg/ml of NZM CDR swap variants, followed by monoclonal antibodies at 2\n\u03bcg/ml concentration and 1/2,500 AP-conjugated goat anti-human IgG,\nFc\u03b3 fragment specific antibody. A heat map of the patterns of antibody\nbinding to the 64 NZM CDR swap variants was computed by using the default\nclustering parameters of the heatmap.2 function from \u2018gplots\u2019\npackage in R in which the Euclidean metric and complete aggregation method were\nselected.",
            "cite_spans": [],
            "section": "ELISA assays for screening and characterization of anti-NZM\nantibodies ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "To study the kinetics of interaction of NZM-specific monoclonal ADAs,\nNZM IgG (50 nM) was stabilized in 10 mM acetate buffer, pH 4.5, and immobilized\nonto a EDC/NHS pre-activated ProteOn sensor chip (Biorad) through amine\ncoupling; unreacted groups were blocked by injection of ethanolamine HCl (1 M).\nHEPES buffered saline (HBS) (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005%\nsurfactant Tween-20) was used as running buffer. All injections were made at\nflow rate of 100 \u03bcl/min. Monoclonal ADAs were diluted to 30 nM and\ninjected onto the NZM coated chip; one channel of the chip was injected with HBS\nand used as reference for the analysis. Injection time and dissociation time\nwere 240 s and 600 s, respectively. The binding interaction of each antibodies\nwith NZM was assessed using a ProteON XPR36 instrument (BioRad). SPR data were\nprocessed with ProteOn Manager Software and ka (1/Ms), kd\n(1/s) and KD (M) parameters were calculated applying the Langmuir fit model.",
            "cite_spans": [],
            "section": "Surface plasmon resonance (SPR) assay ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "Serial dilutions of NZM and NZM variants IgG4 were prepared in MACS\nbuffer (PBS 1% FBS, 2mM EDTA). T cells isolated from healthy donors were used as\nsource of the cell adhesion molecule \u03b14-integrin and added (50,000\ncell/well) to the plates for 30 min, 4\u00b0C. T cells were washed and stained\nwith 3.75 \u03bcg/ml Alexa Fluor 647\u2013conjugated goat anti-human IgG\n(Jackson ImmunoResearch, cat. no. 109-606-170) for 30 min, 4\u00b0C. Cells\nwere washed and analyzed by FACS. NZM binding was calculated as percentage of\nIgG+ stained cells. To study NZM neutralization, NZM-mFc was\ndiluted to 5 ng/ml (final concentration) in MACS buffer (PBS 1% FBS, 2mM EDTA)\nand incubated with titrated monoclonal antibodies for 1 h, 37\u00b0C. T cells\nwere added to the plates for 30 min, 4\u00b0C, then washed and stained with\nsecondary goat anti-mouse-IgG-PE (SouthernBiotech, cat. no. 1030-09) at 1\n\u03bcg/ml for 30 min, 4\u00b0C. Cells were washed and analyzed by FACS. NZM\nneutralization was calculated for each well as percentage of inhibition of\nbinding of NZM-mFc to T cells with the following formula: 1 \u2013 % of cells\nstained by NZM-mFc. Gates were defined based on negative and positive\ncontrols.",
            "cite_spans": [],
            "section": "NZM binding and inhibition of NZM binding assays ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "NZM, NAA32 and NAA84 antibodies were produced as antigen-binding\nfragments and purified on IMAC (HitrapTM IMAC HP, GE Healthcare). Stable\ncomplexes of NZM-NAA32 and NZM-NAA84 were prepared in D-PBS buffer (PBS\nDulbecco\u2019s Gibco 14190-094) at 1.5:1 molar ratio, purified by\nsize-exclusion chromatography (Superdex 200, GE healthcare) and concentrated to\n10 mg/ml. Crystal were grown by vapor diffusion with a well solution containing\n1.7 M sodium malonate pH 6 at 292 K (NZM-NAA32) or 35 % PEG400, 200 mM NaCl, 4 %\nMPD, 100 mM MES pH 6 (NZM-NAA84), and they typically appeared within a week.\nCrystals were flash frozen and x-ray data were collected at the European\nSynchrotron Radiation Facility (Beamline ID30A-1, Grenoble) using MxCube2\nsoftware. Data collection and processing statistics are outlined in Supplementary Table 3.\nStructure solution was performed by molecular replacement using MOLREP (version\n11.6.03)26 through the\nCCP4 suite (version 7.0.058)27\nand crystallographic refinement was carried out using BUSTER (version\n2.11.7)28. The shape\ncorrelation statistic Sc of protein interface was calculated with CCP4.\nSuperimposition was performed using the structure of the NZM-\u03b14\u03b27\nintegrin complex as a reference (4IRZ, https://www.rcsb.org/).\nSurface area is calculated based on Van der Waals surfaces of atoms of NZM lying\nat 4\u00c5 distance from any atom of NAA32 or NAA84. For deimmunization of\nNZM, the CDR2 of the light chain of the antibody was modelled by mutating\nresidues that were positioned at more than 4.0 \u00c5 distance from\n\u03b14-integrin as observed in the 4IRZ structure and did not affect the\nconformation of the antibody CDR region. A non-exhaustive search was performed\nand a number of potential mutations were selected for mutagenesis.",
            "cite_spans": [
                {
                    "start": 916,
                    "end": 918,
                    "mention": "26",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 959,
                    "end": 961,
                    "mention": "27",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1039,
                    "end": 1041,
                    "mention": "28",
                    "ref_id": "BIBREF20"
                }
            ],
            "section": "X-ray crystallography and structure-guided deimmunization ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "T cells were cultured in RPMI 1640 medium supplemented with 2 mM\nglutamine, 1% (v/v) nonessential amino acids, 1% (v/v) sodium pyruvate,\npenicillin (50 U/ml), streptomycin (50 \u03bcg/ml) (all from Invitrogen) and\n5% heat-inactivated human serum (Swiss Red Cross). Sorted memory CD4+\nT cells were labelled with 5-(and 6)-carboxyfluorescein diacetate succinimidyl\nester (CFSE, ThermoFisher) and cultured at a ratio of 2:1 with irradiated\nautologous monocytes untreated or pre-pulsed for 2-3 h with a peptide pool\n(15mers overlapping of 10) covering the entire sequence of the variable region\nof the NZM heavy and light chains (NZM peptide pool, 3 \u03bcM per peptide,\nproduced by A&A Labs). After 12 days, cells were stained with antibodies\nto CD25\u2013PE (BD Biosciences, clone M-A251, cat. no. 555432) and\nICOS\u2013Pacific Blue (Biolegend, clone C398.4A, cat. no. 313522).",
            "cite_spans": [],
            "section": "Ex-vivo stimulation of memory CD4+ T\ncells ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "Proliferating activated T cells from ex-vivo stimulated\ncultures were sorted as CFSElowCD25+ICOS+ and\ncloned by limiting dilution. T cell clones reactivity was determined by\nstimulation with irradiated autologous monocytes or B cells, untreated or\npre-pulsed for 2-3 h with NZM peptide pool (3 \u03bcM per peptide) or, in some\nexperiments, with recombinant NZM (5 \u03bcg/ml). T cell clones proliferation\nwas measured on day 3 after 16 h incubation with 1 \u03bcCi/ml\n[methyl-3H]thymidine (Perkin Elmer). Positive T cell clones were\nselected based on a cut-off value of (i) counts per minute (cpm) with antigen\nand antigen-presenting cells (APCs) \u22651000, and (ii) stimulation index\n\u22651.5 (cpm with antigen and APCs / cpm with APCs only). To determine MHC\nrestriction, stimulation assay was performed in the absence or presence of\nblocking anti-MHC-II monoclonal antibodies produced in house from hybridoma cell\nlines (anti-HLA-DR, clone L243 from ATCC, cat. no. HB-55; anti-HLA-DQ, clone\nSPVL329; anti-HLA-DP,\nclone B7/2130). Epitope\nmapping was performed by stimulation of T cell clones with irradiated\nEBV-immortalized B-cell (EBV-B) clones, untreated or pre-pulsed for 2-3 h with\nindividual peptides (15mers overlapping of 10) covering the entire sequence of\nthe variable region of the NZM heavy and light chains (3 \u03bcM per\npeptide).",
            "cite_spans": [
                {
                    "start": 976,
                    "end": 978,
                    "mention": "29",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1004,
                    "end": 1006,
                    "mention": "30",
                    "ref_id": "BIBREF23"
                }
            ],
            "section": "Isolation of NZM-specific T cell clones ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "Sequence analysis of rearranged TCR V\u03b2 genes of NZM-specific T\ncell clones was performed as previously described31. Briefly, cDNA from individual T cell clones\nwas obtained by reverse transcription of total RNA from\n103-104 cells per reaction. Rearranged TCR V\u03b2\ngenes were PCR amplified using forward primer pool targeting V\u03b2 genes,\nand reverse primer pairing to C1\u2013C2 \u03b2-chain constant region.\nSequence amplification was assessed through agarose gel electrophoresis;\nsuccessfully amplified fragments were sequenced by Sanger method, and TCR\nsequence annotation was carried out by using IMGT/V-QUEST algorithm23.",
            "cite_spans": [
                {
                    "start": 112,
                    "end": 114,
                    "mention": "31",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 608,
                    "end": 610,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "Sequence analysis of TCR V\u03b2 genes ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "HLA genotype of the patients was determined by reverse sequence-specific\noligonucleotides probes (revPCR-SSO) DNA typing (LABType, One Lambda Inc.)\nperformed at the IRCCS San Matteo Hospital Foundation, Pavia, Italy. Predicted\nIC50 (nM) binding values of all theoretical NZM-derived peptides (15mers\noverlapping of 14) to HLA-DRB1 alleles carried by the two patients and to a\nreference set of nine HLA-DRB1 and HLA-DRB3/4/5 alleles including DRB1*0301,\nDRB1*0701, DRB1*1501, DRB3*0101, DRB3*0202, DRB4*0101, DRB5*010115 and DRB1*13:01/14:0116 were calculated using\nNetMHCIIpan 3.2 server (http://www.cbs.dtu.dk/services/NetMHCIIpan-3.2/)14.",
            "cite_spans": [
                {
                    "start": 517,
                    "end": 519,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 540,
                    "end": 542,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 637,
                    "end": 639,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "HLA typing and peptide-MHC-II binding affinity predictions ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "NZM-specific EBV-B clones isolated from the two patients were pulsed\novernight with 5 \u03bcg/ml NZM at a cellular density of 5x106\ncells/ml. MHC-II complexes were purified from about 109 NZM-pulsed\nEBV-B cells with a protocol adapted from Bassani-Sternberg M. et al32. Briefly, the B cells were\nlysed with 0.25% sodium deoxycholate, 1% octyl-\u03b2-D glucopyranoside\n(Sigma), 0.2 mM iodoacetamide, 1 mM EDTA, and Complete Protease Inhibitor\nCocktail (Roche) in PBS at 4\u00b0C for 1 h. The lysates were cleared by 20\nmin centrifugation at 18,000 g at 4\u00b0C, and MHC-II complexes were purified\nby immunoaffinity chromatography with the anti-HLA-DR/DP/DQ HB-145 monoclonal\nantibody produced in house from hybridoma cell line IVA12 (ATCC, cat. no.\nHB-145) and covalently bound to Protein-A Sepharose beads (Thermo Fisher\nScientific). In detail, the cleared lysates were loaded 3 times into the\naffinity columns at 4\u00b0C, and subsequently washed at 4\u00b0C with 10\ncolumn volumes of 150 mM NaCl, 20 mM Tris\u2022HCl, pH 8 (buffer A); 10 column\nvolumes of 400 mM NaCl, 20 mM Tris\u2022HCl, pH 8; 10 column volumes of buffer\nA; and finally 10 column volumes of 20 mM Tris\u2022HCl, pH 8. The HLA-II\ncomplexes were eluted at room temperature by addition of 500 \u00b5l of 0.1 M\nacetic acid, in total five elutions for each sample. Small aliquots of each\neluted fraction were analyzed by 12% SDS-PAGE to evaluate yield and purity of\nMHC-II complexes. Sep-Pak tC18 (Waters, Milford, MA) cartridges were used for\nfurther separation of peptides from MHC-II subunits. The cartridges were\nprewashed with 80% acetonitrile (AcN) in 0.5% formic acid, followed by 0.2%\ntrifluoroacetic acid (TFA), and subsequently loaded 3 times with each fraction\neluted from the immunoaffinity column. After loading, the cartridges were washed\nwith 0.2% TFA, and the peptides were separated from the more hydrophobic MHC-II\nchains by elution with 30% AcN in 0.2% TFA. The peptides were further purified\nusing a Silica C18 column tip (Harvard Apparatus, Holliston, MA) and eluted\nagain with 30% AcN in 0.2% TFA. Finally, the peptides were concentrated by\nvacuum centrifugation, and resuspended in 2% AcN, 0.1% TFA, 0.5% formic acid for\nMS analysis.",
            "cite_spans": [
                {
                    "start": 261,
                    "end": 263,
                    "mention": "32",
                    "ref_id": "BIBREF25"
                }
            ],
            "section": "Purification of MHC-II presented peptides ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "MHC-II peptides were separated on an EASY-nLC 1200 HPLC system coupled\nonline to a Q Exactive mass HF spectrometer via a nanoelectrospray source\n(Thermo Fisher Scientific). Peptides were loaded in buffer A (0.1% formic acid)\non in-house packed columns (75 \u03bcm inner diameter, 50 cm length, and 1.9\n\u03bcm C18 particles from Dr. Maisch GmbH) and eluted with a non-linear 120\nmin gradient of 5%\u201360% buffer B (80% ACN, 0.1% formic acid) at a flow\nrate of 250 nl/min and a column temperature of 50\u00b0C. The Q Exactive was\noperated in a data dependent mode with a survey scan range of 300-1650 m/z and a\nresolution of 60,000 at m/z 200. Up to 10 most abundant isotope patterns with a\ncharge \u2265 1 were isolated with a 1.8 Th wide isolation window and\nsubjected to higher-energy C-trap dissociation (HCD) fragmentation at a\nnormalized collision energy of 27. Fragmentation spectra were acquired with a\nresolution of 15,000 at m/z 200. Dynamic exclusion of sequenced peptides was set\nto 30 s to reduce the number of repeated sequences. Thresholds for the ion\ninjection time and ion target values were set to 80 ms and 3E6 for the survey\nscans and 120 ms and 1E5 for the MS/MS scans, respectively. Data were acquired\nusing the Xcalibur software (Thermo Scientific). MaxQuant software was used to\nanalyze mass spectrometry raw files. MS/MS spectra were searched against the\nfull-length NZM heavy and light chains sequences, the human Uniprot FASTA\ndatabase, and a common contaminants database (247 entries) by the Andromeda\nsearch engine33. N-terminal\nacetylation and methionine oxidation were set as variable modifications; no\nfixed modifications were selected; the enzyme specificity was set to\n\u201cunspecific\u201d with a minimum peptide length of 8 amino acids. A\nfalse discovery rate (FDR) of 1% was required for peptides. Peptide\nidentification was performed with an allowed precursor mass deviation of up to\n4.5 ppm and an allowed fragment mass deviation of 20 ppm; \u201cmatch between\nruns\u201d option was disabled.",
            "cite_spans": [
                {
                    "start": 1519,
                    "end": 1521,
                    "mention": "33",
                    "ref_id": "BIBREF26"
                }
            ],
            "section": "Liquid chromatography\u2013mass spectrometry (LC-MS/MS) and data\nanalysis ::: Online Methods",
            "ref_spans": []
        },
        {
            "text": "GraphPad Prism 7 software was used for to perform all the statistical\nanalyses. EC50 (ng/ml) and IC90 (ng/ml) values were calculated for every\nantibody tested with the different ELISA assays and the inhibition of NZM\nbinding assay, respectively, by nonlinear regression analysis using the GraphPad\nPrism 7 software. A two-tailed Spearman\u2019s correlation was performed to\ncorrelate NZM neutralization (IC90) with association constant (ka)\nand dissociation constant (kd). \u201cn\u201d indicates the\nnumber of antibodies tested. With 17 or more pairs, GraphPad Prism 7 software\ncomputes an approximate P value for nonparametric correlation. An extremely\nsignificant P value is indicated as P < 0.0001.",
            "cite_spans": [],
            "section": "Statistical analysis ::: Online Methods",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "FIGREF0": {
            "text": "Fig. 1: The colored cells show the binding of the antibodies to six selected NZM variants\nin which individual CDRs were swapped with the counterparts of the human\nscaffold antibody used for NZM humanization (H, heavy chain; L, light chain; 1,\nCDR1; 2, CDR2; 3, CDR3). Shown is the percentage of binding of the antibodies to\nthe NZM CDR swap variants relative to NZM, as tested by ELISA, with a\nthree-color gradation scale from minimum (0%, blue) to maximum (100%, white). OD\nvalues and exact % binding values are shown in Source Data 1.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 2: a, Dose-dependent inhibition of NZM binding to T cells of four\nrepresentative antibodies (two NAbs in black and two BAbs in red) compared to an\nunrelated antibody used as a control (representative of n = 2 independent\nexperiments). The dotted line indicates the 90% of inhibition. b,\nPositive and negative selection strengths (\u03a3) in CDRs and FRs of 18 NAb\nand 12 BAb heavy chain sequences from patient A (black and dotted black lines)\nand 10 BAb heavy chain sequences from patient B (red line) estimated using the\nBayesian estimation of Antigen-driven SELectIoN (BASELINe), which compares the\nobserved frequencies of replacement and silent mutations with the expected\nmutations. c, Kinetics of binding of two representative antibodies\n(NAA84 and NAA32) to different doses of NZM as measured by SPR (representative\nof n = 2 independent experiments). The dotted line separates the association and\nthe dissociation phase. RU, resonance units. d, Correlation of NZM\nneutralization (expressed as IC90, i.e. the antibody concentration required for\n90% inhibition of NZM binding to T cells) with association constant\n(ka, upper panel) and dissociation constant (kd, lower\npanel) of n = 40 antibodies measured through SPR (representative of n = 2\nexperiments). BAbs and NAbs are shown as red and black symbols (circle for\npatient A and diamond for patient B), respectively. A two-tailed\nSpearman\u2019s correlation was performed; r coefficient, 0.4070\n(ka) and 0.7673 (kd); 95% confidence interval, 0.09993\nto 0.6433 (ka) and 0.5928 to 0.8730 (kd). e,\nComparison of binding to NZM expressed as half-maximal effective concentration,\nEC50 (upper panel) and NZM neutralization expressed as IC90 (lower panel)\nbetween the unmutated common ancestor (UCA) and the wild type (WT) versions of\nseven representative antibodies (four BAbs and three NAbs) (representative of n\n= 2 independent experiments). The dotted line indicates the threshold of\nneutralization set at 1,000 ng/ml.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Fig. 3: a, Superimposition of the antigen-binding fragment of NZM in complex\nwith NAA84 (NAb, green) and NAA32 (BAb, cyan). NZM heavy and light chains are\nshown in salmon and slate blue, respectively. Proteins are displayed in ribbon\ndiagram. b, Alignment of the NZM residues that are recognized by\nNAA32, NAA84 and \u03b14 integrin. c, Detailed visualization of\nthe interacting interfaces of NZM and NAA32 (left) and NAA84 (right). The\nantibodies are shown as ribbon diagrams with overlapping surfaces. The Sc values\nwere 0.696 and 0.707 for NAA32/NZM and NAA84/NZM complexes, respectively.",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Fig. 4: a, Proliferative response of NZM-reactive T cell clones isolated\nafter ex-vivo stimulation of memory CD4+ T cells,\nupon re-stimulation with the overlapping peptide pool covering the entire\nsequences of the variable regions of the NZM heavy and light chains.\nProliferation was assessed on day 3 after 16 h pulse with\n[3H]-thymidine. Data are expressed as counts per minute (cpm).\nUnstim., unstimulated T cells. b, TCR V\u03b2 gene repertoire of\nNZM-reactive CD4+ T cell clones isolated from MS patients A and B.\nThe y-axis indicates the number of unique clonotypes identified. c,\nEpitope mapping of NZM-specific CD4+ T cell clones isolated from\npatients A and B. The epitopes were identified by screening the T cell clones\nwith overlapping peptides spanning the NZM heavy and light chain variable\nregion. The left y-axis indicates the frequency of T cell clones reactive to\neach peptide. The right y-axis indicates the percentage of CDR residues within\neach peptide shown as filled areas in the background (representative of n = 2\nexperiments). d, Mass spectrometry-based MHC peptidomics of\nNZM-specific B cell clones pulsed with NZM. Each line represents a unique\nMHC-II-bound peptide identified in n = 2 independent experiments. Dashed lines\nindicates peptides belonging to both NZM and B cell receptor of the\nantigen-presenting cells. The y-axis indicates the number of unique peptides\noverlapping in the same NZM region. e, Comparison of the amino acid\nsequences of the LCFR2-CDR2 epitope of NZM and the five variants\nengineered for the drug deimmunization. f, Binding of NZM variants\nto \u03b14 integrin expressed on T cells analyzed by flow cytometry. The NZM\nvariants are color coded as depicted in panel e. An antibody with different\nspecificity was used a negative control (black curve). g,\nProliferation of three NZM-LCFR2-CDR2-reactive T cell clones (A6, A11\nand A13) after stimulation with autologous B cells pulsed with NZM and the five\nengineered variants (representative of n = 2 independent experiments). The bars\nshow the mean proliferation. h, Predicted binding affinities of\n15mer peptides spanning the light chain CDR2 region of NZM variants to a\nreference set of nine DRB1 and DRB3/4/5 alleles (DRB1*0301, DRB1*0701,\nDRB1*1301, DRB1*1401, DRB1*1501, DRB3*0101, DRB3*0202, DRB4*0101,\nDRB5*0101)15,16. The NZM variants are color\ncoded as depicted in panel e. The affinities are shown as reciprocal median IC50\n(nM) values. The dotted lines define the thresholds of high-affinity binding set\nat 100 nM and low-affinity binding set at 300 nM.",
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Extended Data Fig. 1: a, Alignment of NZM heavy and light chain variable\nregions (NZM VH and NZM VL) to the human scaffold antibody counterparts\n(21/28\u2019CL and REI) used for NZM humanization. Mutated residues are\nshown in red. Dots indicate the same residue. b, Scheme of the\n8 heavy and 8 light chains variants of NZM that were combined in an 8x8\nmatrix to express 64 different NZM CDR swap variants. c,\nCluster analysis of binding of 30 antibodies isolated from patient A to the\n64 NZM swap variants by ELISA. BAbs and NAbs are indicated on the x-axis in\nred and black, respectively. The NZM swap variants are shown on the right\ny-axis (H, heavy chain; L, light chain; 1, CDR1; 2, CDR2; 3, CDR3). Optical\ndensity (OD) values are shown with a two-color gradation scale from minimum\n(white) to maximum (blue).",
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Extended Data Fig. 2: a, Closer view of the interaction interface between NZM\nand NAA32 (left) and NAA84 (right). Epitope and paratope residues are shown\nin solid sticks. Proteins are displayed in ribbon diagram. The empty space\nin the interface between the NZM and NAA32 or NAA84 is represented as orange\nor purple surface, respectively, in two different orientations\nb, Superimposition of the antigen-binding fragment of NZM\nin complex with NAA84 (NAb, green), NAA32 (BAb, cyan) and \u03b14-integrin\n(orange). NZM heavy and light chains are shown in salmon and slate blue,\nrespectively. Proteins are displayed in ribbon diagram.",
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Extended Data Fig. 3: Flow cytometry analysis of memory CD4+ T cells at day 12\nafter ex-vivo stimulation with irradiated autologous\nmonocytes untreated (upper panels) or pre-pulsed with NZM peptide pool\n(lower panels). CFSElowCD25+ICOS+ T cells\nreactive to NZM peptide pool were FACS-sorted and cloned by limiting\ndilution (representative of n = 2 biologically independent samples).",
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Extended Data Fig. 4: a, MHC restriction of NZM-reactive T cell clones.\nNZM-specific CD4+ T cell clones isolated from patient A (upper\npanel) and patient B (lower panel) were stimulated with antigen-pulsed\nautologous APCs in the absence or presence of blocking anti-MHC-II antibody\n(anti-HLA-DR, clone L243; anti-HLA-DQ, clone SPVL3; anti-HLA-DP, clone\nB7/21). Proliferation was measured on day 3 after a 16-h pulse with\n[3H]-thymidine, and is expressed as counts per minute (cpm).\nInhibition of T cell proliferation was >80% only in the presence of\nthe anti-HLA-DR antibody. b and c, Predicted\nbinding affinities of all theoretical 15mer peptides derived from NZM heavy\nchain (HC) and light chain (LC) to HLA-DRB1 alleles carried by the two\npatients (b), or to a reference set of nine HLA-DRB1 and HLA-DRB3/4/5\nalleles (c). The affinities are shown as reciprocal IC50 (nM) values. The\ndotted lines define the thresholds of high-affinity binding set at 100 nM\nand low-affinity binding set at 300 nM. d, Predicted binding\naffinities of 15mer peptides spanning the light chain CDR2 region of NZM\nvariants to HLA-DRB1 alleles carried by patient A (DRB1*14:01 and\nDRB1*16:01) and patient B (DRB1*0701). The affinities are shown as\nreciprocal median IC50 (nM) values. The dotted lines define the thresholds\nof high-affinity binding set at 100 nM and low-affinity binding set at 300\nnM.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "A Review on Clinical Pharmacokinetics, Pharmacodynamics, and\npharmacogenomics of natalizumab: A Humanized Anti-alpha4 Integrin Monoclonal\nAntibody",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fang-Hong",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shi-Ying",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shun-Guo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Min-Ling",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Curr Drug Metab",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Antibodies to interferon beta in patients with multiple sclerosis\nreceiving CinnoVex, rebif, and betaferon",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zare",
                    "suffix": ""
                },
                {
                    "first": "SH",
                    "middle": [],
                    "last": "Zarkesh-Esfahani",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gharagozloo",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Shaygannejad",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Korean Med Sci",
            "volume": "28",
            "issn": "",
            "pages": "1801-1806",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Immunogenicity of infliximab and adalimumab: what is its role in\nhypersensitivity and modulation of therapeutic efficacy and\nsafety?",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Murdaca",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Expert Opin Drug Saf",
            "volume": "15",
            "issn": "",
            "pages": "43-52",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "An efficient method to make human monoclonal antibodies from\nmemory B cells: potent neutralization of SARS coronavirus",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Traggiai",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nat Med",
            "volume": "10",
            "issn": "",
            "pages": "871-875",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "How natalizumab binds and antagonizes alpha4\nintegrins",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Schurpf",
                    "suffix": ""
                },
                {
                    "first": "TA",
                    "middle": [],
                    "last": "Springer",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Biol Chem",
            "volume": "288",
            "issn": "",
            "pages": "32314-32325",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Improved methods for predicting peptide binding affinity to MHC\nclass II molecules",
            "authors": [
                {
                    "first": "KK",
                    "middle": [],
                    "last": "Jensen",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Immunology",
            "volume": "154",
            "issn": "",
            "pages": "394-406",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Development and validation of a broad scheme for prediction of\nHLA class II restricted T cell epitopes",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Paul",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Immunol Methods",
            "volume": "422",
            "issn": "",
            "pages": "28-34",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Natalizumab-related anaphylactoid reactions in MS patients are\nassociated with HLA class II alleles",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "de la Hera",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Neurol Neuroimmunol Neuroinflamm",
            "volume": "1",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Anti-idiotypic antibodies: biological function and structural\nstudies",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Pan",
                    "suffix": ""
                },
                {
                    "first": "SC",
                    "middle": [],
                    "last": "Yuhasz",
                    "suffix": ""
                },
                {
                    "first": "LM",
                    "middle": [],
                    "last": "Amzel",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "FASEB J",
            "volume": "9",
            "issn": "",
            "pages": "43-49",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Neutralizing capacity of monoclonal and polyclonal\nanti-natalizumab antibodies: The immune response to antibody therapeutics\npreferentially targets the antigen-binding site",
            "authors": [
                {
                    "first": "KA",
                    "middle": [],
                    "last": "van Schie",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Allergy Clin Immunol",
            "volume": "139",
            "issn": "",
            "pages": "1035-1037 e1036",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Kinetic maturation of an immune response",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Foote",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Milstein",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Nature",
            "volume": "352",
            "issn": "",
            "pages": "530-532",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Natalizumab therapy for multiple sclerosis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chataway",
                    "suffix": ""
                },
                {
                    "first": "DH",
                    "middle": [],
                    "last": "Miller",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Neurotherapeutics",
            "volume": "10",
            "issn": "",
            "pages": "19-28",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Characterization of CD4 T Cell Epitopes of Infliximab and\nRituximab Identified from Healthy Donors",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hamze",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Front Immunol",
            "volume": "8",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "The immunogenicity of humanized and fully human antibodies:\nresidual immunogenicity resides in the CDR regions",
            "authors": [
                {
                    "first": "FA",
                    "middle": [],
                    "last": "Harding",
                    "suffix": ""
                },
                {
                    "first": "MM",
                    "middle": [],
                    "last": "Stickler",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Razo",
                    "suffix": ""
                },
                {
                    "first": "RB",
                    "middle": [],
                    "last": "DuBridge",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "MAbs",
            "volume": "2",
            "issn": "",
            "pages": "256-265",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Efficient generation of monoclonal antibodies from single human B\ncells by single cell RT-PCR and expression vector cloning",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tiller",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Immunol Methods",
            "volume": "329",
            "issn": "",
            "pages": "112-124",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "IMGT, the international ImMunoGeneTics information\nsystem",
            "authors": [
                {
                    "first": "MP",
                    "middle": [],
                    "last": "Lefranc",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Nucleic Acids Res",
            "volume": "37",
            "issn": "",
            "pages": "D1006-1012",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Quantifying selection in high-throughput Immunoglobulin\nsequencing data sets",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Yaari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Uduman",
                    "suffix": ""
                },
                {
                    "first": "SH",
                    "middle": [],
                    "last": "Kleinstein",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nucleic Acids Res",
            "volume": "40",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Change-O: a toolkit for analyzing large-scale B cell\nimmunoglobulin repertoire sequencing data",
            "authors": [
                {
                    "first": "NT",
                    "middle": [],
                    "last": "Gupta",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Bioinformatics",
            "volume": "31",
            "issn": "",
            "pages": "3356-3358",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "MOLREP: an automated program for molecular\nreplacement",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Vagin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Teplyakov",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "J Appl Cryst",
            "volume": "30",
            "issn": "",
            "pages": "1022-1025",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Overview of the CCP4 suite and current\ndevelopments",
            "authors": [
                {
                    "first": "MD",
                    "middle": [],
                    "last": "Winn",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Acta Crystallogr D Biol Crystallogr",
            "volume": "67",
            "issn": "",
            "pages": "235-242",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Bricogne",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "BUSTER version 2.11.7",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Characterization of monoclonal antibodies against cell surface\nmolecules associated with cytotoxic activity of natural and activated killer\ncells and cloned CTL lines",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Spits",
                    "suffix": ""
                }
            ],
            "year": 1983,
            "venue": "Hybridoma",
            "volume": "2",
            "issn": "",
            "pages": "423-437",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "The incidence and significance of anti-natalizumab antibodies:\nresults from AFFIRM and SENTINEL",
            "authors": [
                {
                    "first": "PA",
                    "middle": [],
                    "last": "Calabresi",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Neurology",
            "volume": "69",
            "issn": "",
            "pages": "1391-1403",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Detection of a novel human class II HLA antigen",
            "authors": [
                {
                    "first": "AJ",
                    "middle": [],
                    "last": "Watson",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "DeMars",
                    "suffix": ""
                },
                {
                    "first": "IS",
                    "middle": [],
                    "last": "Trowbridge",
                    "suffix": ""
                },
                {
                    "first": "FH",
                    "middle": [],
                    "last": "Bach",
                    "suffix": ""
                }
            ],
            "year": 1983,
            "venue": "Nature",
            "volume": "304",
            "issn": "",
            "pages": "358-361",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "T cells in patients with narcolepsy target self-antigens of\nhypocretin neurons",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Latorre",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nature",
            "volume": "562",
            "issn": "",
            "pages": "63-68",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Mass spectrometry of human leukocyte antigen class I peptidomes\nreveals strong effects of protein abundance and turnover on antigen\npresentation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bassani-Sternberg",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pletscher-Frankild",
                    "suffix": ""
                },
                {
                    "first": "LJ",
                    "middle": [],
                    "last": "Jensen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mann",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Mol Cell Proteomics",
            "volume": "14",
            "issn": "",
            "pages": "658-673",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Andromeda: a peptide search engine integrated into the MaxQuant\nenvironment",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cox",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Proteome Res",
            "volume": "10",
            "issn": "",
            "pages": "1794-1805",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "The PRIDE database and related tools and resources in 2019:\nimproving support for quantification data",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Perez-Riverol",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nucleic Acids Res",
            "volume": "47",
            "issn": "",
            "pages": "D442-D450",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Occurrence of Anti-Drug Antibodies against Interferon-Beta and\nNatalizumab in Multiple Sclerosis: A Collaborative Cohort\nAnalysis",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Bachelet",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "PLoS One",
            "volume": "11",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Standardizing terms, definitions and concepts for describing and\ninterpreting unwanted immunogenicity of biopharmaceuticals: recommendations\nof the Innovative Medicines Initiative ABIRISK consortium",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Rup",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin Exp Immunol",
            "volume": "181",
            "issn": "",
            "pages": "385-400",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Clinical practice of analysis of anti-drug antibodies against\ninterferon beta and natalizumab in multiple sclerosis patients in Europe: A\ndescriptive study of test results",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Link",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "PLoS One",
            "volume": "12",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Rituximab in multiple sclerosis: Frequency and clinical relevance\nof anti-drug antibodies",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Dunn",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Mult Scler",
            "volume": "24",
            "issn": "",
            "pages": "1224-1233",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Incidence and risk factors for adalimumab and infliximab\nanti-drug antibodies in rheumatoid arthritis: A European retrospective\nmulticohort analysis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Quistrebert",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Semin Arthritis Rheum",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Detection and kinetics of persistent neutralizing\nanti-interferon-beta antibodies in patients with multiple sclerosis. Results\nfrom the ABIRISK prospective cohort study",
            "authors": [
                {
                    "first": "PEH",
                    "middle": [],
                    "last": "Jensen",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Neuroimmunol",
            "volume": "326",
            "issn": "",
            "pages": "19-27",
            "other_ids": {
                "DOI": []
            }
        }
    }
}